Video Experimental Relacionado
Updated: Jul 27, 2026
09:33
An Acute Retinal Model for Evaluating Blood Retinal Barrier Breach and Potential Drugs for Treatment
Published on: September 13, 2016
El síndrome de Reye y la aspirina. Evidencia de un efecto dosis-respuesta
P F Pinsky1, E S Hurwitz, L B Schonberger
1Division of Viral Diseases, Centers for Disease Control, Atlanta, GA 30333.
JAMA
|August 5, 1988
Resumen
Este estudio encontró que las dosis más altas de aspirina durante la enfermedad aumentan el riesgo de síndrome de Reye, particularmente los niveles intermedios. La diferencia de dosis fue más significativa en los días 3 y 4 de la enfermedad.
Área de la Ciencia:
- La pediatría es la medicina de los niños.
- Epidemiología La epidemiología.
- Farmacología Farmacología.
Sus antecedentes:
- El síndrome de Reye es una afección rara pero grave que afecta a niños y adolescentes.
- El uso de aspirina se ha relacionado con el síndrome de Reye, pero las relaciones dosis-respuesta requieren más investigación.
Objetivo del estudio:
- Para analizar la relación entre la dosis de aspirina y el desarrollo del síndrome de Reye.
- Para determinar si los niveles específicos de dosis de aspirina representan un mayor riesgo.
Principales métodos:
- Análisis de los datos del Servicio de Salud Pública Estudio principal del Síndrome de Reye y los medicamentos.
- Comparación de las dosis de aspirina recibidas por pacientes con síndrome de Reye versus controles durante enfermedades anteriores.
Principales resultados:
- Los pacientes de caso recibieron dosis diarias medianas y máximas diarias de aspirina significativamente más altas que los controles.
- El riesgo excesivo se asoció principalmente con las dosis intermedias de aspirina (15-27 mg/kg/día).
- La mayor diferencia de dosis entre los pacientes de caso y los controles se produjo en los días 3 y 4 de la enfermedad.
Conclusiones:
- La dosis de aspirina es un factor crítico en el desarrollo del síndrome de Reye.
- Las dosis intermedias de aspirina presentan un riesgo notable.
- Se justifica una mayor investigación sobre el manejo óptimo de la fiebre pediátrica.
Videos de Conceptos Relacionados
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:03Dose-Response Relationship: Overview
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...